A race is under way among pharmaceutical companies to develop drugs that treat a spectrum of liver diseases, including nonalcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver, and its more severe form, nonalcoholic steatohepatitis (NASH).
Echosens will provide a live demonstration of a FibroScan examination, in partnership with Fidelis, at the Department of Veterans Affairs’ (VA) National Veterans Small Business Engagement
FAST is a cost-effective tool to help identify individuals at risk for fibrotic NASH, an asymptomatic progressive liver disease that leads to increased liver-related mortality and morbidity.
Stephen Harrison, MD, from Pinnacle Clinical Research, highlights the importance of new treatment options for patients with nonalcoholic steatohepatitis, findings from the REGENERATE clinical trial that were presented at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting and Postgraduate Course, and more.
Echosens joins the American Liver Foundation in observance of Liver Cancer Awareness Month, urging increased awareness of non-alcoholic fatty liver disease (NAFLD) and its more severe form called non-alcoholic steatohepatitis (NASH
This white paper examines the impact of NAFLD and NASH as both a medical and economic crisis among military and civilian populations, and highlights the VA’s strategy to eradicate liver disease, including its broadened contract with Echosens to include the FibroScan mini+ portable technology
Stephen Harrison, MD, from Pinnacle Clinical Research, discusses how to educate patients on nonalcoholic fatty liver disease (NAFLD), lifestyle changes that are crucial for patients with NAFLD, and more.